BMO Capital analyst Evan Seigerman raised the firm’s price target on Eli Lilly (LLY) to $1,100 from $930 and keeps an Outperform rating on the shares. The obesity duopoly tilts further in Lilly’s favor as the company captures more share from Novo (NVO), the analyst tells investors in a research note. Lilly continues to gain ground as demonstrated by Mounjaro/Zepbound TRx overtaking and surpassing Ozempic/Wegovy TRx over recent months, the firm added.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Trump announcement on weight loss drugs scheduled for tomorrow, CBS reports
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!
- Novo Nordisk Stock (NVO) Falls after Medicare Price Deal, Q3 Earnings Miss
- Eli Lilly Stock (LLY) Rises as Competitor Novo Nordisk Cuts Guidance
- Trump Trade: Trump in talks with Lilly, Novo on weight loss drug deal